The laboratory assessment of prolactin status was evaluated by detailed study of 921 subjects (587 normal subjects and 334 patients with pathological conditions). The effect on serum prolactin levels of age, sex, circadian rhythm, pulsatility of secretion, stress, drug ingestion, and pregnancy was defined in normal subjects. The normal prolactin responses to stimulation (TRH, metoclopramide) and suppression (t-dopa, bromocriptine) were also determined. Basal prolactin levels were measured in patients with defined pathological conditions including prolactinoma, idiopathic hyperprolactinaemia, acromegaly, Cushing's disease, chronic renal failure, primary hypothyroidism, pituitary ablation, Kallman's syndrome, Nelson's syndrome, growth hormone deficiency, gonadotrophin deficiency, craniopharyngioma, panhypopituitarism, and chronic progressive arthropathy. Based on these data, a strategy for the routine laboratory assessment of prolactin status is outlined.
Pathological, eg iv Stress v Sleep-related nocturnal rhythm vi Drugs (u) dopamine receptor blockers, ego phenothiazines, metoclopramide (b) dopamine depleting agents, eg , a methyl dopa, reserpine (d others, eg, oestrogens, TRH Prolactin levels were studied in 921 subjects. None was receiving drugs known to affect prolactin secretion unless stated. Samples were taken between 0900 and 1200 unless otherwise indicated. Abnormal prolactin levels were confirmed on at least one further specimen. The following groups were studied: i Newborn ii Pregnancy ii Nursing mothers Physiological, eg Measurement of serum prolactin concentration is now an essential part of the routine investigation of patients with suspected hypothalamic-pituitary dysfunction (Friesen et al., 1972; Kleinberg et al., 1977) ; indeed, hyperprolactinaemia is probably the most frequent hypothalamic-pituitary disorder seen in clinical practice, commonly presenting with amenorrhoea and infertility in women and impotence in men (Friesen and Hwang, 1973; Tyson et al., 1975) . Gross abnormalities of prolactin secretion are readily detected by the measurement of basal prolactin levels, and, in general, the higher the level, thegreater the chance that the patient has a prolactinsecreting adenoma (Kleinberg et al., 1977) . However, pituitary microadenomas are often associated with relatively modest degrees of hyperprolactinaemia and as such may be difficult to distinguish from the many physiological and pathological conditions also associated with this biochemical finding (Table 1) .
We have assessed the importance of some of the factors that are relevant to the interpretation of basal prolactin levels by determining detailed reference ranges in defined groups of patients. We have also compared serum prolactin responses to standardised dynamic tests in normal subjects since thesetests may be useful in the diagnosis of pituitary microadenomas in patients with modest hyperprolactinaemia (up to 1000 mUll) and normal pituitary tomography.
(ii) Hospital inpatients 50 subjects (30 men and 20 women, mean age 48, range 18-86 years) without evidence of renal, endocrine, or malignant disease.
(iii) Hospital outpatients 163 women (mean age 39, range 17-71 years) attending a gynaecology outpatient clinic for the first time. Patients with amenorrhoea or infertility were excluded. If prolactin levels were elevated, a second specimen was taken at the next visit to obtain an estimate of possible stress factors related to hospital attendance.
(iv) Women on oral contraceptive preparations as the sole drug 54 women (mean age 32, range 22-41 years). These patients were sampled between 1800 and 2000.
(v) Women at various stages of uncomplicated pregnancies 104 women (mean age 28, range 17-38 years). Samples were taken at routine clinic visits between 1400 and 1500.
(vi) Children with benign, non-endocrine disease 11 normal babies (6M, 5F) aged less than 3 months and 30 children (l3M, 17F) mean age 5, range 3-13, years.
(b) Serial levels
(i) Within-day variation was studied in six subjects (4M, 2F, mean age 27, range 24-30 years). Blood samples were taken via an intravenous cannula at hourly intervals from 0800 to 2000 during which time subjects maintained normal activity.
(ii) Day-to-day variation was studied in 10 subjects (6M, 4F, mean age 28, range 19-39 years) sampled daily for five days between 0900 and 1200.
(iii) Possible stress of venepuncture was studied in 12 men (6 hospital staff and 6 patients, mean age 27, range 25-34 years). The patients were to undergo elective surgery for non-endocrine conditions the next day. Samples were taken from an intravenous cannula at 1O-minute intervals for 90 minutes.
PATHOLOGICAL CONDITIONS

Hypothalamic-pituitary disease
(i) Miscellaneous hypothalamic-pituitary disorders This heterogenous group consisted of 27 patients (I5M, 12F, mean age 31, range 12-64 years) with the following disorders: Kallman's syndrome, n = 4 (4M); Nelson's syndrome, n = 3 (IM, 2F); growth hormone (GH) deficiency, n = 5 (4M, IF); craniopharyngioma, n = 5 (5F) (2 patients postsurgical treatment, 1 patient post radiation therapy); gonadotrophin deficiency, n = 4 (4M), panhypopituitarism, n = 6 (2M, 4F). Diagnosis in all cases was made on clinical, biochemical, and radiological evidence, and all patients were untreated at the time of sampling apart from the three patients noted. Patients with 'panhypopituitarism' had no clinical or biochemical evidence of any specific endocrinopathy.
(ii) Pituitary tumours This group consisted of 42 patients (10M, 32F, mean age 32, range 16-69 years) in the following categories: prolactinomas, n = 16 (lM, 15F); acromegaly, n = 15 (6M, 9F); Cushing's disease, n = 11 (3M, 8F). Diagnosis in all cases was established on clinical and biochemical grounds together with light and electron microscopy and immunoperoxidase studies on surgically removed tissue. In a number of cases, samples were obtained both before and after selective, curative surgical treatment.
Idiopathic hyperprolactinaemia
This group consisted of 10 women (mean age 26, range 16-34 years) who presented with galactorrhoea and/or amenorrhoea and infertility and who had persistent hyperprolactinaemia (ie, elevated PRL levels on at least two separate occasions) with normal pituitary tomography, and no other factor identified to account for their elevated prolactin levels.
Chronic sick
Twenty subjects (8M, 12F, mean age 42, range 27-59 years) who had had chronic progressive arthropathy for more than three years were studied. All patients were taking non-steroidal anti-inflammatory agents as the sole medication.
Renal failure (i) Moderate chronic renal failure (creatinine < 600 fLmolfl) 62 subjects (32M, 30F, mean age 41, range 14-75 years); (ii) severe chronic renal failure (creatinine> 600 fLmolfl) 13 subjects (9M, 4F, mean age 37, range 18-49 years); (iii) regular dialysis treatment (mean creatinine 1300 fLmolfl) 37 subjects (17M, 20F, mean age 33, range 16-52 years). None of these patients was on any drug therapy known to affect prolactin levels, nor had they evidence of clinical endocrinopathy apart from five of the male dialysis patients who were impotent.
Primary hypothyroidism
This group consisted of 50 women (mean age 44, range 24-78 years) with gross primary hypothyroidism (mean T4 = 27 nmol/l, range < 11-48; mean T3 = 0·6 nrnol/l, range <0'4-1'8; TSH all > 50 mUfI). None of these patients had clinical evidence of any other endocrine abnormality.
Pituitary ablation
This group comprised five patients (3M, 2F, mean age 32, range 27-49 years) who were insulindependent diabetics and who had had total hypophysectomy as a therapeutic manoeuvre for severe Results Fig. 1 Basal prolactin levels in 'normal' subjects.
STATISTICAL METHODS
Since the distribution of prolactin levels within the groups studied was non-Gaussian, the Mann-Whitney tesl was used to assess statistical significance.
NORMAL SUBJECTS-BASAL SAMPLING
The range of prolactin levels seen in hospital personnel and inpatients (the control range) was 60-375 mUll ( 
:.:.: .:..:... repurified 1251-labelled prolactin (50 fLI) was added, and the mixture was incubated for 24 hours at 4 0 • Bound and free fractions were separated after a further overnight incubation with precipitating donkey anti-rabbit serum.
The detection limit of the assay was 30 mUll, and mean precision was 5 % CV (within batch) and
10% CV (between batch). Prolactin levels in serum and plasma were not significantly different, nor in specimens frozen immediately in a dry ice mixture or allowed to freeze at -20 0 • Serum samples were routinely assayed, blood being separated within 12 hours of sampling, and serum was stored at -20 0 until assay.
Drug therapy
Samples were obtained from 68 patients (38M, 30F, mean age 37, range 16-72 years) who were on longterm therapy with drugs which may affect basal prolactin levels, viz, phenothiazines, n 21; a-methyl dopa, n = 35; tricyclic antidepressants, n = 8; metoclopramide, n = 2; reserpine, n = 2). proliferative retinopathy. Macroscopically, hypophysectomy had been complete, and samples were obtained from seven months to two years postoperatively.
DYNAMIC TESTS OF PROLACTIN SECRETION (i) Thyrotrophin releasing hormone (TRH-Roche), 200 fLg, was given intravenously to 24 healthy subjects (l4M, IOF, meanage 29, range 24-33 years) and blood was collected by serial venepuncture at 0, 20, and 60 minutes.
(ii) Maxolon (metoclopramide monohydrochloride-Beecham), 10 mg, was given intravenously to 12 subjects (6M, 6F, mean age 28, range 25-33 years), and blood samples were withdrawn at 0 15,30,60, and 120 minutes.
(iii) L-dopa (Roche), 500 mg orally, was taken by eight subjects (5M, 3F, mean age 29, range 26-33 years), and blood samples were withdrawn at 0, 1,1'5,2,3, 5, and 7 hours after ingestion of the drug.
(iv) Parlodel (Bromocriptine-Sandoz), 2'5 rng orally, was taken by three subjects (2M, 1F, mean age 28, range 26-30 years) after a meal, and blood samples were collected at 0, 1,1'5,2,3,5, and 7 hours thereafter.
Whereas in the TRH tests blood was collected by repeated venepuncture, in all other tests samples were taken via an indwelling, intravenous cannula kept patent by heparinised saline. All subjects studied were fit and healthy and on no drug therapy; they maintained normal activity during these tests. No side effects were noted apart from postural hypotension and vomiting after bromocriptine administration, thus restricting the number of subjects receiving this test.
RADIOIMMUNOASSAY OF PROLACTIN
Serum prolactin levels were measured by a specific radioimmunoassay using MRC prolactin preparation 751504 (650 mU/ampoule) as standard. Purified human prolactin (Dr. H. Friesen 75.7.10) was iodinated by the lactoperoxidase method and purified by Sephadex G 150 chromatography; the monomer peak was retained for use as tracer. Before its addition to an assay, the tracer was further repurified by Sephadex G 150 chromatography in a 10 ml disposable pipette. 50 fLI aliquots of standard or sample were incubated with 50 fLI rabbit anti-prolactin There was no significant trend in basal prolactin concentration in any of the 12 subjects in whom venesection was carried out at 10-minute intervals after insertion of an indwelling intravenous cannula, (p < 0'00(5) are noted even in the first trimester of pregnancy, and concentrations rise until term with a wide scatter. Oral contraceptive therapy and long-term therapy with other defined drugs are associated with significant hyperprolactinaemia (p < 0'005).
Eighteen of 163 patients (II %J attending a gynaecology clinic for the first time were found to have prolactin levels outwith the control range. On subsequent sampling 12 of these patients (7 %) were found to have levels within the upper end of the control range while the remaining six patients had persistent hyperprolactinaemia. Four of these patients were found subsequently to be taking drugs known to be associated with hyperprolactinaemia (oral contraceptive therapy n = 3, metoc1opramide n = 1). Two patients (1000 and 1614 mUll) had unexplained hyperprolactinaemia and are now undergoing detailed assessment of their hypothalamic-pituitary function. No significant sex difference in basal prolactin levels was observed, as may be seen in Fig. 2 , which shows the relationship between prolactin level and age in both men and women as well as in children. Significantly elevated prolactin levels (p < 0,(05) are seen in infants under the age of 3 months when compared both with older children and with adults. Although, in male subjects, there is a trend towards lower basal prolactin levels with increasing age, this does not reach statistical significance. In female subjects, however, the trend is more marked, and women of over 50 years have significantly lower prolactin levels (p < 0·005) than younger women. pnlll1L1/1 the mean CY for the group being 11 % (range 7-17%).
Throughout the day, however, a clear circadian pattern of prolactin secretion was observed (Fig. 3) . Between 0800 and 0900 (mean PRL 236m UII, range 100-414) and between 1700 and 2000 (mean PRL 195 mUll, range 86-291) prolactin levels were significantly higher (p < 0.(05) than between 0900 and 1200 (mean PRL 133 mUll, range 71-208).
In addition, circulating prolactin varies in the same individual from day to day, the degree of variability being slightly, though not significantly, more marked in female (mean CY 28 %, range 25-32 %) than in male subjects (mean CY 20 %, range 9-29 %). response to both stimulation tests, female subjects had significantly greater prolactin reserve than did male subjects. This finding is in contrast to the prolactin response to suppression tests which was similar for both male and female subjects. Bromocriptine administration resulted in a more profound and prolonged suppression of prolactin levels than did L-dopa (Table 3) .
Fig. 5a
Prolactin response to TRH stimulation in 'normal' subjects.
DYNAMIC TESTS OF PROLACTIN SECRETION
Administration of TRH (Fig. 5a ) and metoclopramide ( Fig. 5b) resulted in a prompt rise in circulating prolactin levels. The response evoked was greater in magnitude (p < 0.(05) and more prolonged in duration after metoclopramide administration. In
PATHOLOGICAL CONDITIONS
The range of prolactin levels seen in a defined selection of pathological conditions is shown in Table 2 and Figure 4 . Of patients with miscellaneous hypothalamicpituitary disease, only three diagnostic categories were associated with abnormal prolactin levels, viz:
(i) Craniopharyngioma-in which one untreated patient had an elevated prolactin level of 600 mUll, and a further patient, treated by external irradiation, had a grossly elevated level of 2800 mU/1.
(ii) One out of four patients with isolated gonadotrophin deficiency had a persistently modestly elevated basal prolactin level at 480 mU/1.
(iii) Three of the five patients who otherwise showed panhypopituitarism were found to have modestly elevated prolactin levels (up to 750 mU/I), in contrast to the uniformly undetectable levels seen in patients with panhypopituitarism after elective surgical pituitary ablation.
Most patients who had prolactin-secreting tumours of the pituitary gland, as expected, had grossly elevated circulating prolactin levels. However, five of these patients (31 %) had only moderately elevated levels (up to 1200 mUll), and there was overlap in basal prolactin levels with patients who had idiopathic hyperprolactinaemia.
Seven of 15 (47%) untreated acromegalic patients were found to have hyperprolactinaemia; in all but two of the nine patients who underwent selective curative surgical treatment, prolactin levels were significantly (p < 0.(05) reduced by the treatment. A group of patients with active Cushing's disease had a mean prolactin level significantly higher (p < 0·05) than that of a group of control subjects, although only three of the patients had frankly abnormal levels. As in acromegalic subjects, selective, curative microsurgery was associated with a fall in prolactin level.
The prevalence of hyperprolactinaemia in female patients who were hypothyroid was 40 % (20 patients), the levels ranging from 360 to 2400 mU/1. Hyperprolactinaemia occurred in 10 patients (16%) with moderate chronic renal failure but was more cornmon both in severe chronic renal failure (77%) and in dialysis patients (78 %).
Patients with chronic progressive arthropathy had prolactin levels within the reference range.
Discussion
The basal prolactin levels seen in healthy neonates, children, and adults in this study are consistent with those previously described in smaller groups of subjects (Friesen and Hwang, 1973; Guyda and Friesen, 1973) . Even in healthy individuals, however, several factors may affect prolactin status, and appropriate interpretation of a given result demands adequate reference data in relation to factors such as sex, age, circadian rhythm, pulsatility of secretion, stress, and drug ingestion (Jeffcoate, 1978) .
Mean basal prolactin levels are usually higher in female than in male subjects (Ehara et al., 1973; Friesen and Hwang, 1973) though witha considerable overlap in their ranges (Frantz, 1978) . In our study, no statistically significant sex difference was observed, although no account was taken of the stage of the menstrual cycle in women. Some authors have demonstrated significantly higher prolactin levels in the peri-ovulatory and luteal phases of the cycle when compared with follicular phase levels (Franchimont et al., 1976) but other investigators have failed to demonstrate any consistent pattern in circulating prolactin during the menstrual cycle (Ehara et al., 1973; McNeilly and Hagen, 1974) . It is of interest, however, that in postmenopausal women we have observed a significant fall in prolactin levels, which may well be oestrogen-related, since no similar fall is seen in ageing males; Thorner and his colleagues have demonstrated a rise in serum prolactin levels, which correlates with oestradiol levels in pubertal girls, but not boys (Thorner et al., 1977) . Thus, age is also a factor that may affect basal prolactin status, at least in female subjects. The origin of the hyperprolactinaemia in neonates is not clear but is presumed to be of fetoplacental origin (Guyda and Friesen, 1973) although it may also be oestrogenrelated.
It is established that considerably elevated prolactin levels occur during the hours of sleep (Ehara et al., 1973; Sassin et al., 1973) , and it has been reported that, in the early hours of the morning, prolactin levels may still be significantly elevated (Friesen and Hwang, 1973) . Our data confirm this and, in addition, suggest a diurnal variation in prolactin secretion during waking hours, with higher prolactin levels in the early morning and a trend towards higher levels again in the evening. The ideal sampling time thus would be between 0900 and 1200, when prolactin levels are at their nadir. The degree of individual variability in prolactin secretion from day to day is modest but is more marked in female than in male subjects, an observation which again may be related to the oestrogen status of the subject. This modest varia-tion in prolactin levels from day to day, together with the relative consistency in prolactin concentrations noted over a much shorter period of time (90 minutes), suggests that for confirmation of hyperprolactinaemia repeated sampling on several different days may be of more value than the usually advocated repeated sampling over a short period via an indwelling cannula.
Prolactin release arising from the stress associated with major surgery or insulin-induced hypoglycaemia is well established (Noel et al., 1972) . The incidence of hyperprolactinaemia, attributable to the 'psychic' stress of either hospital attendance or venepuncture is poorly documented however, although a recent study suggests that 19 %of women attending an infertility clinic have elevated prolactin levels after clinical interview (Koninckx, 1978) . In the present study we have failed to demonstrate any rise in prolactin levels as a result of venepuncture per se, but 7% of women attending a general gynaecology clinic for the first time were noted to have elevated prolactin levels, which were normal on subsequent sampling and which may have been related to the stress of hospital attendance. It is clearly necessary, therefore, to confirm consistent elevation of prolactin levels before attributing any clinical abnormality to hyperprolactinaemia.
The relation between prolactin and oestrogen levels in pregnancy is familiar, and the stimulant effect of oestrogens on prolactin secretion has also been demonstrated experimentally (Carlson et al., 1973) . Hence, it is not surprising that patients taking oestrogen-containing, oral contraceptive preparations have a mean prolactin level higher than that of control subjects. Indeed, 44% had frankly abnormal levels. Similarly, other drugs have been associated with hyperprolactinaernia, for example, o-methyl dopa (Steiner et al., 1976) , phenothiazines (de Rivera et al., 1976) , and metoclopramide (McCallum et al., 1976) , and in the present study, long-term therapy with o-methyl dopa phenothiazines, tricyclic antidepressants, metoclopramide, and reserpine were all associated with significantly elevated prolactin levels. The degree of hyperprolactinaemia, however, was modest, 95 % of patients having levels less than 700 mUll. This finding may account for the fact that none of these patients had any symptoms or signs that might be attributed to hyperprolactinaemia.
We have confirmed that several pathological conditions may be associated with elevated prolactin levels although not chronic ill health per se, The postulated aetiological mechanisms involved in the production of hyperprolactinaemia are diverse: for example, disruption of the hypothalamicpituitary stalk as may occur in pituitary tumours with suprasellar extension; deranged hypothalamic control mechanisms to account for idiopathic hyperprolactinaemia; excessive stimulation by naturally occurring agents such as TRH in primary hypothyroidism; and altered renal metabolism of prolactin with progressive uraemia. Autonomous production of prolactin by pituitary adenomas clearly results in the highest circulating levels of prolactin (Kleinberg et al., 1977; Franz, 1978) , but, in our series, 30 % of confirmed tumours were associated with minor elevations in basal prolactin levels, such that they could not be distinguished from other causes of hyperprolactinaemia on this basis alone.
Since the early reports that TRH and L-dopa evoked, respectively, stimulation and suppression of prolactin levels in normal individuals (Friesen et al., 1972; L'Hermite et al., 1972) , it has been hoped that tests of the autonomy of prolactin secretion would prove of value in the identification of tumour-associated hyperprolactinaernia. Initial results were disappointing (Lamberts et al., 1976) but recently we, and others, have found dynamic tests, particularly stimulation tests, to be of value in the identification of prolactin-secreting tumours, particularly when the degree of hyperprolactinaemia is modest and pituitary radiology is entirely normal (Healy et al., 1977; Kleinberg et al., 1977; Cowden et al., 1979) .
It is now established that metoclopramide is a potent stimulus to prolactin secretion (Delitala et al., 1976; Judd et al., 1976; McCallum et al., 1976) , and indeed not only is the magnitude of prolactin response greater than that seen after TRH, but it is also more prolonged in duration. In response to both TRH and metocIopramide stimulation, prolactin release is considerably greater in women, a finding that may reflect greater oestrogen-related prolactin reserve despite remarkably similar basal levels in men and women. Acute administration of L-dopa and bromocriptine results in prompt suppression of prolactin levels; the extent and duration of suppression of prolactin levels, however, are much greater after bromocriptine. These different patterns of prolactin suppression in response to the acute administration of L-dopa and bromocriptine may well be related to the respective failure and success of these agents observed in the long-term treatment of hyperprolactinaemic syndromes (Friesen et al., 1972; Thorner et al., 1977) .
In conclusion, we suggest the following strategy for the laboratory assessment of prolactin status: 1 Draw blood sample, under resting basal conditions, ideally between 0900 and 1200, though sampling between 0900 and 1700 is acceptable. 2 If an elevated prolactin level is demonstrated, when compared with appropriate age and sex related control subjects, exclude:
(i) drug therapy (including oral contraceptive) (ii) pregnancy (iii) primary hypothyroidism (iv) chronic renal failure (v) hypothalamic-pituitary disease Relate level to appropriate reference ranges in groups (i) to (v). 3 Repeat sample: (i) If both levels> 700 mUll, this is unlikely to be due to stress (ii) If both levels > 1000 mUll, this is likely to be due to pituitary tumour. 4 If levels are modest and unexplained, and pituitary tomography is normal, undertake stimulation tests of prolactin secretion and compare responses with appropriate male or female control subjects.
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